吡柔比星早期灌注治疗预防膀胱癌复发的疗效观察  

Effect on prophase intravesical instillation of pirarubicin for preventing recurrence of bladder cancer

作　　者：沈俭[1] 陈建华[2] 俞奇伟[1] 沈杰[1] 孙鹏[1] 

机构地区：[1]上海交通大学医学院附属新华医院崇明分院泌尿外科,上海202150 [2]上海交通大学医学院附属新华医院泌尿外科,上海200092

出　　处：《世界临床药物》2011年第5期284-286,共3页World Clinical Drug

摘　　要：目的评估经尿道膀胱肿瘤电切(TURBT)术后吡柔比星早期膀胱灌注预防膀胱癌复发的疗效。方法选取90例膀胱癌患者,随机分为早期灌注组(A组,n=45)和常规维持灌注组(B组,n=45)。A组于TURBT术后6 h行吡柔比星30 mg膀胱内灌注,术后1周两组均行吡柔比星常规灌注化疗,比较两组膀胱癌的复发率。结果 A、B两组膀胱癌的复发率分别为6.7%和17.8%,组间差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论 TUBBT术后吡柔比星早期灌注化疗能降低膀胱癌复发,疗效确切且安全耐受。Objective To evaluate the effect on prophase intravesical instillation of pirarubicin for preventing from recurrence of bladder cancer after transurethral bladder tumor resection（TURBT）.Methods Ninety cases of bladder cancer patients were randomly divided into prophase instillation group（group A,n=45） and routine instillation group（group B,n=45）.Group A accepted intravesical instillation of pirarubicin 30 mg within 6 h after operation.Then two groups started routine treatment of pirarubicin after one week of operation.The recurrence rates were compared between two groups.Results The recurrence rates of group A and B were 6.7% and 17.8%,and there was significant difference between two groups（P0.05）.No severe adverse reactions in two groups were observed.Conclusion The recurrence rate of bladder cancer may reduce by prophase intravesical instillation of pirarubicin after TURBT.It is effective and safe.

关 键 词：吡柔比星 膀胱癌 灌注 复发 不良反应 

分 类 号：R979.1[医药卫生—药品] R737.14[医药卫生—药学]